NCT00129844View on ClinicalTrials.gov

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

December 31, 2007

Conditions

AdenocarcinomaNon-Small-Cell Lung CarcinomaLung Neoplasms

Interventions

DRUG

Motexafin Gadolinium

Trial Locations (16)

Unknown

Fountain Valley

Los Angeles

Palm Springs

Columbia

St Louis

Omaha

Albuquerque

Rochester

Akron

Knoxville

Nashville

Calgary

Edmonton

Kingston

Ottawa

Montreal

Sponsors

Lead Sponsor

Pharmacyclics LLC.

All Listed Sponsors

lead

Pharmacyclics LLC.

INDUSTRY